antibacterial

  • Low interest in antibacterials

    Hedwig Kresse, lead infectious disease analyst at Datamonitor , believes that Big Pharma’s low interest in antibacterials means that the only defence is improved hygiene in hospitals and stringent measures to prevent spread: “Over the past dec…

    antibacterial | 01 September 2010

  • Biota Acquires Antibacterial Assets of Prolysis

    Biota Holdings has announced the acquisition of the key assets and programs of Prolysis, an antibacterial drug discovery company located in Oxford, England. Prolysis has two primary projects that are focused on new antibiotics for multiple drug r…

    antibacterial | 26 November 2009

  • Biota to Acquire Antibacterial Assets of MaxThera

    Biota Holdings has announced the acquisition of the assets and drug development programs of MaxThera, an antibacterial drug discovery company located in Boston, US. The acquisition is subject to the satisfaction of certain conditions which the former…

    antibacterial | 20 November 2009

  • Genetic Chemistry, US Army Research Office Sign $22.8M Antibacterial Contract

    Genetic Chemistry, a subsidiary of Evolva SA, has signed a contract with the US Army Research Office (ARO), working in conjunction with the Defense Threat Reduction Agency (DTRA), to discover advanced therapeutics against the gram-negative bacteria p…

    antibacterial | 01 June 2008